| Literature DB >> 30292418 |
Marco Radovic1, Ravindran Kanesvaran2, Achim Rittmeyer3, Martin Früh4, Fabrizio Minervini5, Markus Glatzer1, Paul Martin Putora6.
Abstract
Lung cancer is the leading cause of cancer death worldwide. Older patients represent approximately half of the patient population and optimal management of these patients is challenging. In early-stagenon-small cell lung cancer (NSCLC), lobectomy should be considered in fit older patients. For unfit patients, stereotactic body radiotherapy (SBRT) represents a good alternative. While data on the benefit and risk of concurrent chemo-radiotherapy (cCRT) in older patients with locally advanced NSCLC is conflicting, age alone should not preclude cCRT. Multidisciplinary collaboration is essential for appropriate patient selection. In limited disease small cell lung cancer (SCLC), older patients appear to benefit similarly from standard treatment compared to their younger counterparts, however, with a higher risk of toxicity. Appropriately selected older patients with lung cancer seem to derive as much benefit from active oncological treatment as their younger counterparts. Geriatric screening tests and comprehensive geriatric assessments (CGA) can be helpful when choosing between treatment strategies. Older patients are at risk for under-treatment; this should be avoided by proper selection and multidisciplinary management. This review outlines the management of lung cancer in older patients.Entities:
Year: 2018 PMID: 30292418 DOI: 10.1016/j.jgo.2018.09.005
Source DB: PubMed Journal: J Geriatr Oncol ISSN: 1879-4068 Impact factor: 3.599